灵康药业：2025年年度业绩预告

Group 1 - The core viewpoint of the article is that Lingkang Pharmaceutical (603669) has announced its 2025 annual performance forecast, expecting a net profit attributable to the parent company of approximately -127 million yuan, which represents a reduction in losses of about 2.88% compared to the same period last year [1] Group 2 - The company anticipates a net profit loss for 2025, indicating ongoing financial challenges [1] - The forecast reflects a slight improvement in financial performance compared to the previous year, suggesting potential operational adjustments [1]